---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104218"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:53:56.031051+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics FY2025 net loss $22.4M; cash $13.1M, outlines 2026 milestones for REYOBIQ and CNSide

## Summary
- Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.
- Cash and investments $13.1M at Dec 31, 2025 (up from $3.6M); raised $15M gross in upsized public offering.
- CNSide lab licensed in 49 states; coverage agreements with Humana and UnitedHealthcare reach ~67M lives.
- 2026 milestones: REYOBIQ Phase 2 LM data Q3 2026, GBM data Q4; CNSide target >1,250 annual test orders, breakeven by 2027.
- Secured AMA Category III CPT code for convection-enhanced delivery with REYOBIQ, unlocking market access.

## SEC filing metadata
- accession: 0001193125-26-104218
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/0001193125-26-104218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/pstv-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104218
- JSON: https://secwatch.observer/filing/0001193125-26-104218.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.